24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Mapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas FeasibleBiomarker ID'd for Pregnancy-Induced Glucose IntoleranceTransplant of Insulin-Producing Cells Offers Hope Against Type 1 DiabetesVitamin D Doesn't Impact Insulin Sensitivity, Secretion in T2DMPCSK9 Linked to New-Onset Diabetes After Renal TransplantLinear Association for Weight Loss, HbA1c Reduction in T2DMHealth Tip: Make Food More FlavorfulAntioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DMHealth Tip: Create a Sick-Day Plan for DiabetesRed Wine Antioxidant Might Help Diabetics' ArteriesCardiometabolic Disease Staging Score Quantifies Diabetes RiskIntense Interval Training Cuts Hypoglycemia Awareness in T1DMDecreased Cortical Thickness Seen in Type 2 DiabetesAlgorithm Integrated Into App Forecasts Glucose LevelsThree Anti-VEGF Treatments Effective for Diabetic RetinopathyType 2 Diabetes May Be Bad for Brain HealthHealth Tip: Coping With the 'Dawn Phenomenon'Plasma Uric Acid Lowering Tied to Drop in Systolic BP in T1DMHealth Tip: Continuous Glucose Monitoring DevicesT2DM Risk Cut by Variant in Sulfonylurea Receptor EncoderObesity Quadruples Kids' Type 2 Diabetes Risk: StudyDoctors Encouraged to Assess Driving Risks for T1DM PatientsEarly Glycemic Control With Metformin Cuts CVD EventsWhen Is It Safe to Drive With Type 1 Diabetes?Nurse-Led Intervention Helps With Diabetes ControlIs Annual Eye Exam a Must for People With Type 1 Diabetes?RUNX1 May Play Role in Proliferative Diabetic RetinopathyFast-Acting Insulin Aspart Ups Glycemic Control in T1DMDiabetes Continues to Be a Significant Public Health BurdenContinuous Glucose Monitoring Improves Quality of Life in T1DMDiabetes Continues Its Relentless RiseContinuous Subcutaneous Insulin Infusion Bests Injections in T2DMPrevalence of Metformin Use 0.7 Percent in PrediabetesENDO: Distinct Urine Metabolite Profile in Obese Youth With T2DMRace Plays Role in Heart, Diabetes Risk, Even at Normal WeightPredictive Low-Glucose Mgmt Cuts Hypoglycemic Events in T1DTeleretinal Diabetic Retinopathy Screening Ups Screening RatesDAPT Cessation Patterns Vary With Diabetes Status After PCIIncreased Use of Newer Meds for Diabetic Nephropathy in the U.S.What Drugs Work Best for Diabetic Nerve Pain?
Links
Related Topics

Medical Disorders

PCSK9 Linked to New-Onset Diabetes After Renal Transplant


HealthDay News
Updated: May 9th 2017

new article illustration

TUESDAY, May 9, 2017 (HealthDay News) -- For renal transplant recipients (RTRs) without diabetes, circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with new-onset diabetes after transplantation (NODAT), according to a study published online May 1 in Diabetes Care.

Michele F. Eisenga, M.D., from the University of Groningen in the Netherlands, and colleagues examined the correlation between serum PCSK9 levels and NODAT development among RTRs without diabetes with a functional graft for at least one year.

Serum PCSK9 was 107.1 ± 43.4 µg/L in 453 RTRs. The researchers found that 70 RTRs developed NODAT, 123 died, and 59 developed graft failure during a median follow-up of 10 years. NODAT occurred more often in the upper versus the two lowest tertiles of PCSK9 (23 versus 12 percent; P < 0.001). PCSK9 correlated with the development of NODAT (hazard ratio, 1.34; 95 percent confidence interval, 1.10 to 1.63 per standard deviation change; P = 0.004). The correlation was independent of confounding variables, including statin use. There was no correlation for PCSK9 with all-cause mortality, cardiovascular mortality, or graft failure.

"Circulating PCSK9 is associated with NODAT in RTRs," the authors write. "The PCSK9 pathway may contribute to the pathogenesis of NODAT."

PCSK9 was measured at Lilly Research Laboratories (Eli Lilly and Company) for free.

Abstract/Full Text (subscription or payment may be required)